What Is BIIB Fair Value?
Biogen (BIIB) fair value estimate using multiple valuation models, updated daily.
As of July 16, 2026, Biogen (BIIB) has a composite fair value estimate of $396.49 based on four valuation models: DCF (41% weight), Graham Number (29% weight), PEG (29% weight), and DDM (0% weight). The current market price is $197.24, suggesting the stock is undervalued by 101.0%.
Data as of July 16, 2026 (today)
Composite Fair Value
Undervalued3 of 4 models$396.49
vs. current price of $197.24(+101.0%)
How Is BIIB Fair Value Calculated?
Four independent models estimate what BIIB is worth. Each uses different inputs and assumptions. The composite blends them by weight.
BIIB Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
41% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$627.23
+218.0%Undervalued
Inputs used
DDM (Dividend Discount Model)
0% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
N/A
This stock does not pay a dividend, so the DDM cannot be applied. The composite adjusts by redistributing this weight to the other models.
BIIB Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
29% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$189.15
-4.1%Fair Value
Inputs used
PEG (Price/Earnings to Growth)
29% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$125.84
-36.2%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $197.24 is 218.0% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $2.06B | $1.96B |
| Year 2 | $2.21B | $2.00B |
| Year 3 | $2.36B | $2.03B |
| Year 4 | $2.52B | $2.07B |
| Year 5 | $2.70B | $2.10B |
| Year 6 | $2.88B | $2.14B |
| Year 7 | $3.08B | $2.18B |
| Year 8 | $3.30B | $2.21B |
| Year 9 | $3.52B | $2.25B |
| Year 10 | $3.77B | $2.29B |
| Terminal Value | $148.10B | $89.99B |
What Are BIIB's Key Financial Metrics?
Earnings & Growth
Current Price
$197.24
EPS (TTM)
$9.57
Forward P/E
11.9
Profit Margin
13.8%
Cash & Balance Sheet
Free Cash Flow
1.9B
EBITDA
3.5B
Book Value
$126.37
Total Debt
6.6B
What Do Analysts Say About BIIB?
Low
$157.00
Average
$225.45
High
$300.00
Upside
+14.3%
BIIB Fair Value FAQ
What is the fair value of BIIB?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), BIIB's estimated fair value is $396.49. The stock is currently trading at $197.24, which makes it undervalued by our analysis.
How is BIIB's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is BIIB overvalued or undervalued?
Based on our analysis, BIIB is undervalued. The current price of $197.24 is 101.0% below our estimated fair value of $396.49.
What do Wall Street analysts say about BIIB?
31 analysts cover Biogen with a consensus rating of "Buy." The average price target is $225.45, ranging from $157.00 to $300.00. This implies 14.3% upside from the current price.